JP2013512277A5 - - Google Patents

Download PDF

Info

Publication number
JP2013512277A5
JP2013512277A5 JP2012542076A JP2012542076A JP2013512277A5 JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5 JP 2012542076 A JP2012542076 A JP 2012542076A JP 2012542076 A JP2012542076 A JP 2012542076A JP 2013512277 A5 JP2013512277 A5 JP 2013512277A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutically acceptable
group
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012542076A
Other languages
English (en)
Japanese (ja)
Other versions
JP5709889B2 (ja
JP2013512277A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/057359 external-priority patent/WO2011066183A1/en
Publication of JP2013512277A publication Critical patent/JP2013512277A/ja
Publication of JP2013512277A5 publication Critical patent/JP2013512277A5/ja
Application granted granted Critical
Publication of JP5709889B2 publication Critical patent/JP5709889B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012542076A 2009-11-30 2010-11-19 新規スピロピペリジン化合物 Expired - Fee Related JP5709889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26518109P 2009-11-30 2009-11-30
US61/265,181 2009-11-30
PCT/US2010/057359 WO2011066183A1 (en) 2009-11-30 2010-11-19 Novel spiropiperidine compounds

Publications (3)

Publication Number Publication Date
JP2013512277A JP2013512277A (ja) 2013-04-11
JP2013512277A5 true JP2013512277A5 (https=) 2013-11-14
JP5709889B2 JP5709889B2 (ja) 2015-04-30

Family

ID=43384775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542076A Expired - Fee Related JP5709889B2 (ja) 2009-11-30 2010-11-19 新規スピロピペリジン化合物

Country Status (26)

Country Link
US (1) US8822486B2 (https=)
EP (1) EP2507228B1 (https=)
JP (1) JP5709889B2 (https=)
KR (1) KR101410103B1 (https=)
CN (1) CN102648195B (https=)
AR (1) AR078948A1 (https=)
AU (1) AU2010324987B2 (https=)
BR (1) BR112012012903A2 (https=)
CA (1) CA2781292C (https=)
CL (1) CL2012001321A1 (https=)
CR (1) CR20120296A (https=)
DO (1) DOP2012000139A (https=)
EA (1) EA020507B1 (https=)
EC (1) ECSP12011930A (https=)
ES (1) ES2526568T3 (https=)
GT (1) GT201200164A (https=)
IL (1) IL219594A0 (https=)
MA (1) MA33840B1 (https=)
MX (1) MX2012006233A (https=)
NZ (1) NZ600203A (https=)
PE (1) PE20121474A1 (https=)
PH (1) PH12012501052A1 (https=)
TN (1) TN2012000248A1 (https=)
TW (1) TW201141866A (https=)
WO (1) WO2011066183A1 (https=)
ZA (1) ZA201203055B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
EP2970161B8 (en) * 2013-03-14 2018-10-17 Janssen Pharmaceutica NV Gpr120 agonists for the treatment of type ii diabetes
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN110590767B (zh) * 2019-08-29 2021-10-08 南方科技大学 一种合成amg837的方法
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
CN1768041A (zh) * 2003-04-04 2006-05-03 麦克公司 作为黑皮质素-4受体激动剂的酰化螺哌啶衍生物
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) * 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1795527B1 (en) * 2004-09-07 2009-04-22 Banyu Pharmaceutical Co., Ltd. Carbamoyl-substituted spiro derivative
CA2657639A1 (en) * 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
AU2008241490B2 (en) * 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
BRPI0818687A2 (pt) * 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament

Similar Documents

Publication Publication Date Title
JP2013512277A5 (https=)
JP2013508279A5 (https=)
JP2012526728A5 (https=)
JP2013507423A5 (https=)
JP2014500861A5 (https=)
JP2013537203A5 (https=)
JP2007302689A5 (https=)
JP2015500843A5 (https=)
JP2016530259A5 (https=)
JP2012512863A5 (https=)
JP2016006118A5 (https=)
JP2013032389A5 (https=)
JP2009523760A5 (https=)
JP2014530900A5 (https=)
JP2013542261A5 (https=)
JP2010077141A5 (https=)
JP2013510123A5 (https=)
JP2006524660A5 (https=)
JP2011504903A5 (https=)
JP2014516033A5 (https=)
JP2011500658A5 (https=)
JP2011518833A5 (https=)
JP2013513607A5 (https=)
JP2015508092A5 (https=)
JP2015516427A5 (https=)